	US 12,281,334 B2
	Multi donor stem cell compositions and methods of making same
Takanori Takebe, Cincinnati, OH (US); Masaki Kimura, Cincinnati, OH (US); and Ran-Ran Zhang, Cincinnati, OH (US)
Assigned to Children's Hospital Medical Center, Cincinnati, OH (US)
Appl. No. 16/603,609
Filed by Children's Hospital Medical Center, Cincinnati, OH (US)
PCT Filed Apr. 13, 2018, PCT No. PCT/US2018/027585 § 371(c)(1), (2) Date Oct. 8, 2019, PCT Pub. No. WO2018/191673, PCT Pub. Date Oct. 18, 2018.
Claims priority of provisional application 62/517,414, filed on Jun. 9, 2017.
Claims priority of provisional application 62/485,562, filed on Apr. 14, 2017.
Prior Publication US 2020/0040309 A1, Feb. 6, 2020
Int. Cl. C12N 5/071 (2010.01); C12N 5/074 (2010.01); G01N 33/50 (2006.01)

CPC C12N 5/0697 (2013.01) [C12N 5/0679 (2013.01); C12N 5/0696 (2013.01); G01N 33/5008 (2013.01); C12N 2500/02 (2013.01); C12N 2501/40 (2013.01)]

9 Claims

1. A method of synchronizing a pooled-precursor cell population comprising a population of induced pluripotent stem cells (iPSCs) derived from more than one individual, the method comprising exposing a pooled-precursor cell population comprising a population of iPSCs derived from more than one individual to a mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) pathway inhibitor and a glycogen synthase kinase-3 (GSK3) pathway inhibitor under a hypoxic condition for a period of time to produce a population of iPSCs with synchronized cell growth.